For immediate release
17 August 2016

Full Year Result 2016
CSL Delivers Another Strong Performance

• Double-digit sales growth in all plasma therapy groups
• Novel recombinant coagulation products approved and launched
• Seqirus formed – business turnaround program on track
• CSL Board to consider further share buyback of ~A$500 million

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016. After excluding the financials relating to the Novartis influenza vaccines business acquired during the year, underlying¹ NPAT grew 5% and earnings per share (EPS) grew 7% on a constant currency (CC)² basis.

HIGHLIGHTS

Financial
• Revenue US$6,129 million
  o Underlying revenue up 8% at CC
• Earnings before interest and tax (EBIT) US$1,438 million
  o Underlying EBIT up 7% at CC
• NPAT US$1,242 million
  o Underlying NPAT up 5% at CC
• EPS US$2.69
  o Reported EPS down 8%
  o Underlying EPS up 7% at CC
• Research and development investment US$614 million
• Final dividend³ of US$0.68 per share, up 3% on PCP
  o Unfranked for Australian tax purposes, payable on 7 October 2016
  o Converted to Australian currency, the final dividend is approximately A$0.89 per share

¹ Underlying excludes financials relating to the Novartis influenza vaccines business (NVS-IV). NVS-IV was acquired on 31 July 2015. See end note for further detail.
² Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.
³ For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.886652 per share (at an exchange rate of A$1.3039/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.943364 per share (at an exchange rate of NZ$1.3873/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$. 
Operational

CSL Behring
- Product sales up 10% at CC
- Idelvion® (rFIX-FP) approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada
- Afstyla® (rFVIII-SC) approved by US FDA
- Respreneza® (AATD) approved by the EMA
- New Privigen® (IVIG) manufacturing facility in Broadmeadows, Australia, approved by US FDA

Influenza (Seqirus)
- Novartis influenza vaccines acquisition closed 31 July 2015
- Seqirus business launched – No. 2 global influenza vaccine leader. Turnaround program on track
- Fluad™ (influenza vaccine) approved by US FDA
- Flucelvax Quadrivalent™ (influenza vaccine) approved by US FDA
- Afluria Quad™ (influenza vaccine) approved by Australian Therapeutics Goods Administration (TGA)

Capital Management
- A$1 billion share buyback⁴ ~92% completed⁵

“2016 has been a transformational year for CSL,” said CSL Chief Executive Officer and Managing Director Paul Perreault. “In our 100th anniversary year, it is clear CSL has evolved from an organization that largely brought international discoveries to Australians - to an established and growing global leader which translates its own early research into commercial medicines for patients in more than 60 countries. While CSL has changed over 100 years, one aspect has not: We continue to be driven by our promise to improve lives. Over the past 12 months we have secured approvals and launched five new products – including our two novel recombinant coagulation products Idelvion® and Afstyla® – an enormous achievement and the fruit of many years of work.”

“CSL Behring, our core business, continues to perform well, delivering double digit sales growth in all biotherapy groups. This includes another outstanding performance by our subcutaneous immunoglobulin product Hizentra®, growing sales by 31%. To support this

---

⁴ CSL reserves the right to terminate buy-backs at any time.
⁵ As at 11 July 2016
growth sustainably into the future, we have a major facilities expansion program underway around the world."

“Early in the financial year, CSL acquired the loss-making influenza vaccines business of Novartis at a steep discount to book value. Combined with our existing flu business, we created Seqirus, the second largest influenza vaccine provider in the world,” added Mr. Perreault. “The Seqirus business turnaround program is now well underway. The transition to quadrivalent influenza vaccines has commenced, we’ve increased production from our unique cell culture facility and we received approval and launched our differentiated adjuvanted influenza vaccine, Flud™. Notably, we were the first manufacturer to have an influenza vaccine released in the US market for its upcoming flu season,” Mr. Perreault added.

OUTLOOK (at FY16 exchange rates)

Commenting on CSL’s outlook, Mr. Perreault said, “At the core, CSL is a growing, broad-based, stable business which generates solid earnings growth. We are igniting this growth with innovative biotechnology advancements, including our newly approved and launched novel recombinant therapies Idelvion® and Afstyla®. In fact, we expect to benefit this year from a full 12 months’ contribution from Idelvion® and Afstyla®. Ongoing demand for our CSL Behring therapies is expected to continue, with ongoing strong performance in differentiated products such as Hizentra®. Our range of specialty plasma products is again expected to grow strongly.”

Mr Perreault added, “The turnaround of Seqirus is on track and is expected to breakeven in FY18. Consistent with previously announced plans, Seqirus is expected to report a loss in the current fiscal year.”

“CSL is well positioned for sustainable growth and delivering shareholder value. CSL Group’s net profit after tax (NPAT) is expected to grow approximately 11%, at constant currency, on the FY16 result after adjusting for the one-off gains and costs associated with the acquisition of the Novartis influenza vaccines business. On the same basis, earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to grow approximately 14% this financial year. Earnings per share (EPS) are again expected to exceed profit growth,” Mr Perreault concluded.
In compiling the company’s financial forecasts for the year ending 30 June 2017 a number of key variables which may have a significant impact on guidance have been identified and these have been included the footnote\(^6\) below.

**OPERATING REVIEW**

**CSL Behring** product sales of US$5,245 million increased 10% at constant currency when compared to the prior comparable period.

**Immunoglobulin** product sales of US$2,457 million grew 11% at constant currency.

The key growth driver has been Hizentra\(^\circledast\), CSL Behring’s subcutaneous immunoglobulin product where demand has been strong in both the US and Europe. Hizentra\(^\circledast\) grew sales 31% at constant currency. New patient starts, selective partnering in the Specialty Pharmacy segment and the increase in home treatment contributed to the strong performance.

Demand for intravenous immunoglobulin has also been solid led by Privigen\(^\circledast\), which delivered sales growth of 7% at constant currency. In the US, market share was maintained in the highly competitive hospital setting. In Europe, Privigen\(^\circledast\) saw strong growth, especially in France and UK, driven by Privigen’s\(^\circledast\) expanded indication to include its use in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The introduction of IG IsoLo\(^\circledast\), a manufacturing step to reduce isoagglutinin levels which contributes to further improving the product safety profile, has been well received. In Australia, Privigen\(^\circledast\) was introduced into the market following a successful tender with Australia’s National Blood Authority.

**Haemophilia product** sales of US$1,000 million grew 4% at constant currency. Plasma derived haemophilia sales grew 14% at constant currency. This increase was largely

---

\(^6\) Key variables that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property.
driven by solid demand for Beriate®, led by Poland and Germany and successful tenders in Russia and Iran. Strong demand for Humate® in the US also contributed. The strong growth in plasma derived therapies was offset to a large extent by the decline in sales of Helixate®, CSL’s licensed recombinant factor VIII product. Competition in this market continues to increase with the launch of new generation recombinant FVIII products including CSL’s recently approved Afstyla®.

**Specialty products sales** of US$977 million grew 11% at constant currency. Sales of Kcentra® (4 factor pro-thrombin complex concentrate) in the US were strong driven by our fully established sales force and greater brand awareness.

Berinert® (C1-esterase inhibitor concentrate) was another solid contributor. Berinert is used for the treatment of acute attacks in patients with hereditary angioedema (HAE). Berinert® has seen strong growth in Europe due to the increased awareness and diagnosis of HAE.

Respreeza® (Alpha-1 Proteinase Inhibitor) was launched in a number of European countries following the granting of marketing authorisation. Respreeza® is a maintenance treatment for severe Alpha-1 Antitrypsin Deficiency patients and has been shown to slow the progression of emphysema. Following the initial launch, Respreeza will be rolled out more broadly in Europe this year.

**Albumin** sales of US$811 million rose 12% at constant currency, driven by ongoing significant global demand particularly in China and the US. In China, demand for albumin is exceptionally strong and is expected to continue. CSL is well positioned with a broad portfolio of products and an extensive distribution network that is focused on the fast growing second and third tier cities in China.

**Seqirus** sales of US$652 million reflects 11 months of sales since the acquisition of Novartis' influenza vaccines business on 31 July 2015. Sales of influenza vaccine were adversely impacted by a mild influenza season in the northern hemisphere. The Seqirus business turnaround program remains on track.

**CSL Intellectual Property** revenue of US$123 million declined 10% at constant currency. The prior comparable period included a payment from CSL’s licensee Janssen

---

7 The Group has recognised a deferred tax asset relating to current year Seqirus losses in the UK on the expectation that the business will generate future taxable profits.
Biotech Inc. to develop and commercialise CSL362, a product used to treat patients with acute myeloid leukaemia.

**CAPITAL MANAGEMENT**

**Share Buyback**

In October 2015, CSL announced its intention to conduct an on-market share buyback of up to A$1 billion. To date, CSL has purchased approximately 9.1 million shares for approximately A$924 million, representing about 92% of the intended buyback program.

*Capital management foreshadowed during FY17*

CSL’s balance sheet remains very sound and appropriately geared. The current cost of debt is at historic lows. Following the completion of the current buyback, which has approximately A$76 million remaining, the Board of Directors will consider a further on-market share buyback program of approximately A$500 million.

During the first half of fiscal 2017, CSL intends to approach the US private placement market to raise approximately US$500 million as part of the company’s overall capital management program.

**CHANGES TO CSL BOARD**

Dr. Tadataka “Tachi” Yamada KBE has been appointed a Director of the Company, effective 1 September 2016. Mr John Akehurst has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016. For further information please see the separate ASX announcement which was issued today.

**DIVIDENDS**

CSL will offer shareholders the opportunity to receive dividend payments in US dollars by direct credit to a US bank account. This option will be available for the 2016 final dividend payment (payment date 7 October 2016). Shareholders who wish to avail themselves of this payment option for the 2016 final dividend payment must provide their valid US bank account details by the dividend record date which is 14 September 2016.
US bank account details can be provided:

- Online at www.investorcentre.com. If not already an existing user, shareholders must create a login in order to provide their payment instruction;
- By calling our Share Registry, Computershare Investor Services, on 1800 646 882 (within Australia) or +61 (03) 9415 4178 (outside Australia);
- By writing to the Share Registry at Computershare Investor Services, GPO Box 2975, Melbourne VIC 3001 and providing the relevant particulars including your SRN or HIN.

FURTHER INFORMATION

Additional details about CSL’s results are included in the company’s 4E statement, investor presentation slides and webcast, all of which can be found on CSL’s website www.csl.com.au. A glossary of medical terms can also be found on the website. For further information, please contact:

Investors:  
Mark Dehring  
Head of Investor Relations  
CSL Limited  
Telephone: +613 9389 3407  
Email: mark.dehring@csl.com.au

Media:  
Jemimah Pentland  
Head of Communications, Asia Pacific  
CSL Limited  
Mobile +61 412 635 483  
Email: jemimah.pentland@csl.com.au
# Group Results

*US Dollars*

<table>
<thead>
<tr>
<th>Full years ended June US$ Millions</th>
<th>FY15 Reported</th>
<th>FY16 Reported</th>
<th>FY16 @CC(^9)</th>
<th>FY16 NVS-IV(^9) @CC</th>
<th>FY16 Underlying(^9) at CC</th>
<th>Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>5,459</td>
<td>5,909</td>
<td>6,210</td>
<td>284</td>
<td>5,926</td>
<td>8.6%</td>
</tr>
<tr>
<td>Other Revenue / Income</td>
<td>169</td>
<td>220</td>
<td>225</td>
<td>62</td>
<td>163</td>
<td></td>
</tr>
<tr>
<td>Total Revenue / Income</td>
<td>5,628</td>
<td>6,129</td>
<td>6,435</td>
<td>346</td>
<td>6,089</td>
<td>8.2%</td>
</tr>
<tr>
<td>Earnings before Interest, Tax, Depreciation &amp; Amortisation</td>
<td>1,939</td>
<td>1,658</td>
<td>1,818</td>
<td>(294)</td>
<td>2,112</td>
<td>7.7%</td>
</tr>
<tr>
<td>Depreciation/Amortisation</td>
<td>181</td>
<td>220</td>
<td>233</td>
<td>27</td>
<td>206</td>
<td></td>
</tr>
<tr>
<td>Earnings before Interest and Tax</td>
<td>1,758</td>
<td>1,438</td>
<td>1,585</td>
<td>(321)</td>
<td>1,906</td>
<td>7.1%</td>
</tr>
<tr>
<td>Gain on Acquisition</td>
<td>44</td>
<td>58</td>
<td>57</td>
<td>3</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Net Interest Expense / (Income)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax Expense</td>
<td>335</td>
<td>314</td>
<td>347</td>
<td>(32)</td>
<td>379</td>
<td></td>
</tr>
<tr>
<td>Net Profit after Tax</td>
<td>1,379</td>
<td>1,242</td>
<td>1,357</td>
<td>(116)</td>
<td>1,473</td>
<td></td>
</tr>
<tr>
<td>NVS-IV one-off (gain)/costs</td>
<td>22</td>
<td>(90)</td>
<td>(90)</td>
<td>(90)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Underlying Net Profit after Tax</td>
<td>1,401</td>
<td>1,152</td>
<td>1,267</td>
<td>(206)</td>
<td>1,473</td>
<td>5.2%</td>
</tr>
</tbody>
</table>

| Total Dividend (US$)              | 1.24         | 1.26         |                |                       |                                |         |
| Final Dividend (US$)              | 0.66         | 0.68         |                |                       |                                | 3.0%    |
| Reported EPS (US$)                | 2.92         | 2.69         |                |                       |                                | (8.0%)  |
| Underlying\(^9\) EPS (US$)       | 2.97         |              |                |                       | 3.19                           | 7.4%    |

---

\(^9\) Novartis influenza vaccines acquisition as from 31 July 2015

\(^9\) Underlying excludes financials relating to the Novartis influenza vaccines business (NVS-IV)
Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior comparable period (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior comparable period (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses (foreign currency effect). The sum of translation currency effect, transaction currency effect and foreign currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.

Summary NPAT adjusted for currency effects

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported net profit after tax</td>
<td>US$1,242.4m</td>
</tr>
<tr>
<td>Translation currency effect (a)</td>
<td>US$85.5m</td>
</tr>
<tr>
<td>Transaction currency effect (b)</td>
<td>US$(7.7m)</td>
</tr>
<tr>
<td>Foreign Currency losses (c)</td>
<td>US$37.2m</td>
</tr>
<tr>
<td>Constant currency net profit after tax *</td>
<td>US$1,357.4m</td>
</tr>
</tbody>
</table>

a) Translation Currency Effect NPAT $85.5m

Average Exchange rates used for calculation in major currencies (twelve months to June 16/June 15) were as follows: USD/EUR (0.90/0.82); USD/CHF (0.98/0.94).

b) Transaction Currency Effect NPAT $(7.7m)

Transaction currency effect is calculated by reference to the applicable prior year exchange rates. The calculation takes into account the timing of sales both internally within the CSL Group (ie from a manufacturer to a distributor) and externally (ie to the final customer) and the relevant exchange rates applicable to each transaction.

c) Foreign Currency Effect NPAT $37.2m

Foreign currency losses during the period as recorded in the financial statements.

Underlying Net Profit after Tax at Constant Currency

At the time of the 2015 results CSL provided guidance to the market excluding the Novartis Influenza business (NVS-IV) that was acquired by the Group on 31 July 2015. Guidance to the market was presented excluding the anticipated financial performance of NVS-IV given the uncertainty around that performance at the time of the publication of the 2015 results.

There are three elements that bridge the constant currency result noted above to the Underlying Net Profit after Tax at constant currency:

d) Operational Performance NVS-IV NPAT $(205.5m)

Operational performance of the NVS-IV business – the business recorded a Net Loss after Tax of $205.5m

e) One off items NPAT $(86.6m)

One off items comprise acquisition and integration costs that were incurred during the year. Acquisition costs include professional fees and travel. Integration costs are those costs incurred in bringing the acquired business into the CSL Group, these include salary costs, professional fees and travel. Together acquisition and integration costs are $86.1m after tax – these costs have been charged to the income statement of the Group.

f) Gain on acquisition NPAT $176.1m

The acquisition gave rise to a gain as the fair value of net assets acquired was greater than the consideration paid. Full details of the gain are included in the financial statements in Note 1b.

Constant currency net profit after tax *  US$1,357.4m

| Operational performance of NVS-IV (d) | US$205.5m   |
| One-off items (e)                     | US$86.6m    |
| Gain on acquisition (f)              | US$(176.1m) |
| FY16 underlying constant currency NPAT | US$1,473.4m |

Summary Sales

| Reported sales                        | US$5,909.5m |
| Currency effect                       | US$300.1m   |
| Constant currency sales (Group)       | US$8,209.6m |
| NVS-IV sales                          | US$283.8m   |
| Underlying FY16 Sales                 | US$5,925.8m |

* Constant currency net profit after tax and sales have not been audited or reviewed in accordance with Australian Auditing Standards.